about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Pfiz­er, No­var­tis tie up to tar­get NASH in crowd­ed field

7 years ago
R&D
Pharma

Bio­gen, Ei­sai re­leas­es four-year da­ta on ad­u­canum­ab; EMA stamps Ei­dos' aT­TR ther­a­py with or­phan des­ig­na­tion

7 years ago
News Briefing

Ul­tragenyx stum­bles with UX007 PhI­II, shares plunge

7 years ago
R&D

No­vo-backed Galec­to Biotech scores €79 mil­lion in Se­ries C fund­ing

7 years ago
Financing

Con­sti­pa­tion drug mak­er Syn­er­gy looks to rene­go­ti­ate bloat­ed loan agree­ment — shares tum­ble

7 years ago
R&D
Pharma

Ver­tex cleans up its pipeline; FDA grants pri­or­i­ty re­view to Jakafi for GVHD

7 years ago
News Briefing

As talk of drug pric­ing takes cen­ter stage, Am­gen slash­es Repatha price by near­ly 60%

7 years ago
Pharma

Trump to un­veil pro­pos­al to re­duce prices on doc­tor-ad­min­is­tered drugs as midterms loom

7 years ago
Pharma

Bay­er, Ori­on prostate can­cer drug de­lays spread of dis­ease in PhI­II, but can it make a mark in a crowd­ed mar­ket?

7 years ago
R&D

Alex­ion doles out $22M up­front for two pre­clin­i­cal RNAi drugs from Dicer­na

7 years ago
Pharma

Nav1.7 anal­gesic fail­ures stack up as Bio­gen aban­dons vixot­rig­ine af­ter lat­est set­back

7 years ago
R&D

NeoGe­nomics spends $125M to ex­pand ops; Cara hires Cel­gene ex­ec as CMO

7 years ago
News Briefing

An­ti­sense start­up Stoke Ther­a­peu­tics se­cures an­oth­er $90M in se­ries B fund­ing

7 years ago
Startups

En­terome for­ti­fies Take­da re­la­tion­ship with $50M up­front to co-de­vel­op Crohn's drug

7 years ago
R&D
Pharma

Med­i­cines Co ex­ecs grab a $33M A round to spin out an in­fec­tious dis­ease out­fit with a pipeline

7 years ago
Financing
Startups

Chip­ping away at Gilead­'s HIV em­pire, GSK's Vi­iV sub­mits NDA for 2-drug HIV reg­i­men -- play­ing vouch­er card for ...

7 years ago
R&D

Am­gen sharp­ens fo­cus on ge­net­ic se­quenc­ing with $66M in­vest­ment

7 years ago
Pharma

Al­ler­gan set to make head­way in crowd­ed CGRP mi­graine mar­ket, as the bat­tle for for­mu­la­ry cov­er­age be­gins

7 years ago
Pharma

Pharnext rare dis­ease drug scores in late-stage study, tee­ing up ap­pli­ca­tions at the FDA and EMA

7 years ago
R&D

Buy­out deal loom­ing, No­vo Nordisk raids As­traZeneca for a new chief to run its strug­gling bio­phar­ma busi­ness

7 years ago
People

Bay­er wins OK for he­mo­phil­ia A treat­ment; Agenus sells off a slice of fu­ture roy­al­ties for $15M

7 years ago
News Briefing

UK ad­vis­es against cov­er­ing No­var­tis' Kym­ri­ah for adults; Ex-Mast chief Bri­an Cul­ley ap­point­ed CEO at Bi­o­Time

7 years ago
News Briefing

As­traZeneca touts ex­tend­ed safe­ty and ef­fi­ca­cy da­ta on Fasen­ra; Vanes­sa King takes the helm at Viri­on

7 years ago
News Briefing

Gala­pa­gos rais­es $300M on the back of first PhI­II fil­go­tinib suc­cess; In­cyte push­es in­to PhI­II with top­i­cal Jakafi

7 years ago
News Briefing
First page Previous page 222324252627 Next page Last page
A service from the Financial Times